Related Experiment Video
Updated: Aug 24, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Prospective strategies to enforce selectively cell death in cancer cells
1Brander Cancer Research Institute, New York Medical College, 19 Bradhurst Ave, Hawthorne, Valhalla, NY 10532, USA.
Abstract:
Although induction of apoptosis (cell death mediated by caspases) determines response to cancer therapy, this approach is limited by lack of selectivity in available apoptosis-inducing agents. Furthermore, most cancers, almost by definition, are resistant to apoptosis, growth arrest and cell senescence. Then, how can anticancer agents kill cancer cell without unacceptable toxicity to a patient? The potential therapeutic approaches range from selective inhibition of antiapoptotic pathways, antiangiogenic therapy, tissue-selective therapy (including immunotherapy) to exploitation of, for example, drug resistance, oncoprotein addiction, unrestricted cell cycles, hypermitogenic and hypoxic features of cancer cells. These overlapping and complementary approaches rely on rational drug combinations (at mechanism-based doses and sequences) aimed at matching targets. To ensure killing of cancer cells selectively, we may combine apoptosis- and senescence-inducing agents with inhibitors of apoptosis (to protect normal cells), inhibitors of signal transduction with cell cycle-dependent chemotherapy, antiangiogenic agents with hypoxia-inducible factor-1 inhibitors, tissue-selective therapy with differentiating agents and activators of death receptors with chemotherapy. In theory, consecutive use of these drug combinations may control cancer.
Insights
Targeted cancer therapies aim to selectively kill cancer cells. Combining apoptosis-inducing agents with other targeted treatments offers a promising strategy to overcome cancer resistance and minimize patient toxicity.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Cancer therapy response is determined by apoptosis induction, but current agents lack selectivity.
- Most cancers exhibit resistance to apoptosis, growth arrest, and senescence.
- Developing anticancer agents with reduced patient toxicity is a critical challenge.
Purpose of the Study:
- To explore novel therapeutic strategies for selective cancer cell killing.
- To identify rational drug combinations that overcome cancer resistance mechanisms.
- To investigate approaches for minimizing off-target toxicity in cancer treatment.
Main Methods:
- Review of potential therapeutic strategies including targeted pathway inhibition, antiangiogenesis, and immunotherapy.
- Analysis of exploiting cancer-specific features like drug resistance and hypermitotic states.
- Conceptualization of mechanism-based drug combinations with optimized doses and sequences.
Main Results:
- Selective inhibition of antiapoptotic pathways and exploitation of cancer cell vulnerabilities are key strategies.
- Rational drug combinations can synergistically target cancer cells.
- Combining apoptosis- and senescence-inducing agents with inhibitors of apoptosis can protect normal cells.
Conclusions:
- Strategic drug combinations offer a theoretical framework for effective cancer control.
- Targeted combinations can overcome apoptosis resistance and reduce toxicity.
- Future cancer therapies may rely on precisely sequenced, mechanism-based drug cocktails.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
05:08Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
Published on: February 17, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...